Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ImmunoGen Inc (NASDAQ:IMGN)

14.28
Delayed Data
As of Aug 28
 0.00 / 0.00%
Today’s Change
5.34
Today|||52-Week Range
19.43
+134.10%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. It also have developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream and then release it once the therapy has reached and entered a cancer cell. The company also uses antibody-drug conjugate targeted antibody payload technology together with strong antibody expertise to develop its own product candidates. ImmunoGen was founded in March 1981 and is headquartered in Waltham, MA.

Contact Information

ImmunoGen, Inc.
830 Winter Street
Waltham Massachusetts 02451-1477
P:(781) 895-0600
Investor Relations:

Employees

Shareholders

Mutual fund holders54.61%
Other institutional38.15%
Individual stakeholders1.15%

Top Executives

Daniel M. JuniusPresident, Chief Executive Officer & Director
David B. JohnstonChief Financial Officer & Executive Vice President
Sandra E. PooleExecutive Vice President-Technical Operations
Richard J. GregoryChief Scientific Officer & Executive VP-Research
Anna BerkenblitChief Medical Officer & Vice President